Literature DB >> 8521881

Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure.

M R Bristow1, E M Gilbert.   

Abstract

Virtually all medications used to treat cardiac problems act through a pharmacological mechanism that immediately improves electrical or mechanical function or inhibits the manifestation of a pathological process. The idea that medical therapy could exert a favourable myocardial effect by fundamentally improving the biological function of cardiac myocytes is novel, and is based on the observation that in heart failure the acute pharmacological effects of beta-blocking agents on left ventricular function are completely different from their long-term effects. beta-blocking agents improve intrinsic systolic function long-term, despite depressing function initially through the pharmacological effect of withdrawing adrenergic drive, indicating that the beneficial effect of this form of therapy is due to improved myocyte biology. Implicit in this observation is that improvement in the fundamental biology of failing cardiac myocytes should favourably affect the natural history of heart failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521881     DOI: 10.1093/eurheartj/16.suppl_f.20

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 2.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 3.  Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.

Authors:  Catherine N Marti; Gregg C Fonarow; Stefan D Anker; Clyde Yancy; Muthiah Vaduganathan; Stephen J Greene; Ali Ahmed; James L Januzzi; Mihai Gheorghiade; Gerasimos Filippatos; Javed Butler
Journal:  Eur J Heart Fail       Date:  2018-12-10       Impact factor: 15.534

4.  Therapeutic Molecular Phenotype of β-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy.

Authors:  David P Kao; Brian D Lowes; Edward M Gilbert; Wayne Minobe; L Elaine Epperson; Leslie K Meyer; Debra A Ferguson; Ann Kirkpatrick Volkman; Ronald Zolty; C Douglas Borg; Robert A Quaife; Michael R Bristow
Journal:  Circ Cardiovasc Genet       Date:  2015-01-30

Review 5.  Ventricular unloading and myocyte recovery: insight gained into the pathophysiology of congestive heart failure.

Authors:  K B Margulies
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

6.  Serial gene expression profiling in the intact human heart.

Authors:  Brian D Lowes; Ronald Zolty; Wayne A Minobe; Alastair D Robertson; Sonia Leach; Lawrence Hunter; Michael R Bristow
Journal:  J Heart Lung Transplant       Date:  2006-04-11       Impact factor: 10.247

7.  Changes in myocardial cytoskeletal intermediate filaments and myocyte contractile dysfunction in dilated cardiomyopathy: an in vivo study in humans.

Authors:  S Di Somma; M Marotta; G Salvatore; G Cudemo; G Cuda; F De Vivo; M P Di Benedetto; F Ciaramella; G Caputo; O de Divitiis
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

8.  Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease.

Authors:  Arvin Halim; Gayatri Narayanan; Takashi Hato; Lilun Ho; Douglas Wan; Andrew M Siedlecki; Eugene P Rhee; Andrew S Allegretti; Sagar U Nigwekar; Daniel Zehnder; Thomas F Hiemstra; Joseph V Bonventre; David M Charytan; Sahir Kalim; Ravi Thadhani; Tzongshi Lu; Kenneth Lim
Journal:  J Am Heart Assoc       Date:  2022-02-18       Impact factor: 6.106

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.